2018
DOI: 10.1038/emm.2017.271
|View full text |Cite
|
Sign up to set email alerts
|

Macrophage migration inhibitory factor mediates peripheral nerve injury-induced hypersensitivity by curbing dopaminergic descending inhibition

Abstract: Our previous works disclosed the contributing role of macrophage migration inhibitory factor (MIF) and dopaminergic inhibition by lysine dimethyltransferase G9a/Glp complex in peripheral nerve injury-induced hypersensitivity. We herein propose that the proinflammatory cytokine MIF participates in the regulation of neuropathic hypersensitivity by interacting with and suppressing the descending dopaminergic system. The lumbar spinal cord (L-SC) and ventral tegmental area (VTA) are two major locations with signif… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(8 citation statements)
references
References 74 publications
0
8
0
Order By: Relevance
“…The specificity of recognition of the MIF "pocket" structure by Iso-1 was shown by X-ray crystallography of Iso-1 bound to MIF (Lubetsky et al, 2002;Trivedi-Parmar and Jorgensen, 2018), reinforcing the widespread use of Iso-1 as the canonical MIF inhibitor. Iso-1 has been used extensively in preclinical studies as a MIF inhibitor, including rodent pain experiments (Wang et al, 2010(Wang et al, , 2018Alexander et al, 2012).…”
Section: Pharmacological Agentsmentioning
confidence: 99%
“…The specificity of recognition of the MIF "pocket" structure by Iso-1 was shown by X-ray crystallography of Iso-1 bound to MIF (Lubetsky et al, 2002;Trivedi-Parmar and Jorgensen, 2018), reinforcing the widespread use of Iso-1 as the canonical MIF inhibitor. Iso-1 has been used extensively in preclinical studies as a MIF inhibitor, including rodent pain experiments (Wang et al, 2010(Wang et al, , 2018Alexander et al, 2012).…”
Section: Pharmacological Agentsmentioning
confidence: 99%
“…Though A9 and A10 neurons extend their projections within the brain, previous studies showed that SCI or peripheral nerve injury can change the firing properties of these neurons as well as the release of DA. This suggests an indirect effect of injury on these neurons, such as adaptation or neuroinflammation [ 43 – 45 ]. Following SCI, the increase of gamma-aminobutyric acidergic (GABAergic) neuronal activity in the A10 region suppresses DA neuronal activity and further decreases DA release [ 43 ].…”
Section: Discussionmentioning
confidence: 99%
“…Following SCI, the increase of gamma-aminobutyric acidergic (GABAergic) neuronal activity in the A10 region suppresses DA neuronal activity and further decreases DA release [ 43 ]. A proinflammatory cytokine, macrophage migration inhibitory factor (MIF), downregulates DA release after peripheral nerve injury [ 45 ]. Collectively, upregulated DA-related genes may be a compensatory response to the deficient release of DA in A9 and A10 nuclei.…”
Section: Discussionmentioning
confidence: 99%
“…The DNMT inhibitor 5‐aza‐2'‐deoxycytidine (5‐Aza‐dC) was obtained from Sigma‐Aldrich and dissolved in 30% DMSO in saline. 5‐Aza‐dC dose was based on previous reports (Fonteneau et al., 2017; Miao et al., 2017; Wang et al., 2018).…”
Section: Methodsmentioning
confidence: 99%